Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications - Test2 - elhamkhani - TriplyDB

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

http://www.wikidata.org/entity/Q35596530

about

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study Ultrasound-based elastography for the diagnosis of portal hypertension in cirrhotics.Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: systematic review and meta-analysis Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis.Transient elastography in clinical detection of liver cirrhosis: A systematic review and meta-analysis.Visualizing the hepatic vascular architecture using superb microvascular imaging in patients with hepatitis C virus: A novel technique.Quantitative comparison of transient elastography (TE), shear wave elastography (SWE) and liver biopsy results of patients with chronic liver disease.A health technology assessment of transient elastography in adult liver disease.Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.Value of radiofrequency ablation in the treatment of hepatocellular carcinoma Hepatitis C Virus and Liver Transplantation.Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma.Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma.Clinical outcomes of compensated and decompensated cirrhosis: A long term study.The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS.Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population.Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis.Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are?Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis Oncogenic potential of hepatitis C virus proteins Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection.Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.The risk of cellulitis in cirrhotic patients: a nationwide population-based study in taiwan Bleeding complications in critically ill patients with liver cirrhosis Comparison of laparoscopic hepatectomy, percutaneous radiofrequency ablation and open hepatectomy in the treatment of small hepatocellular carcinoma.Economic evaluation of delivering hepatitis B vaccine to injection drug users A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland.Disease burden of chronic hepatitis B among immigrants in Canada.

P2860

Q24201588-D995E17F-5152-433E-9494-374ED69F060F Q24680285-8D03938A-5430-465F-9B5D-8478CD672F47 Q26778038-4D7DCB23-7E76-48C7-9425-5A5A22AD3140 Q26864259-46679C4A-C105-49A5-9DCB-F4C13A522641 Q28084154-C95178B1-FA91-402C-9BAF-76F0D0D112B3 Q30374820-7D8C9206-C514-4B35-BE57-218ADE8F5EDB Q30378188-2CA5BF85-F1C7-48B2-B7A0-515A728AF985 Q30403283-E988F683-4B3F-463C-B468-63F0B5D2FF7B Q30442208-9D9D3A9E-2D3E-479D-8EB0-A0BAF81C914C Q33557770-814F073B-14D8-4A86-9ADE-039CE87A73A0 Q33618516-688313AD-70B6-4AB5-A340-115747ED5C56 Q33661046-7CE9614A-112F-49E2-A843-9C87CE7FBC53 Q33717116-AAC1BDAC-C05E-4F6A-99BB-A46B9347F5BB Q33739952-2482E326-0B13-4F94-884B-39EA0923B3AF Q33867865-AFACD936-012A-4E73-AFFA-8337D709948A Q33948229-0CB146E9-DCC2-426C-B9A4-CFDD6F1E5DEA Q33961656-7A00ADD6-D7F2-4E66-B743-6B7FBEE9DF60 Q34203972-AF4F689F-F921-46F5-85AB-4A81420D9696 Q34233163-7EA1A4EA-5A90-4E20-9A3F-8278C740308F Q34287407-82C9BE9E-58A2-4C8C-928E-B1F019A344F0 Q34365396-D63EF1E3-220E-4E90-8003-CCC8554C2F6A Q34405044-0B3BDECC-26E7-4608-92D2-AC11A194345F Q34690368-17A06CB5-BA7E-4220-8C65-1A3239C4D973 Q34778315-AF5D9239-5D3E-4DEA-9ADE-2753BC613533 Q35131882-D9BBA21A-A1EB-4F27-B345-E3BDCF39D08E Q35135141-4B4B30A6-EEDF-4B2E-BD83-B4A59A8E191E Q35155028-BF0E27B9-DB78-4D97-AE71-E8C38DB25411 Q35261292-5DCA368F-1919-4D8C-A840-F86411D306E7 Q35322521-36975599-1BDD-485D-944E-87E486CB46C4 Q35590977-E6E4D0BE-5204-45C4-9821-11633D4C932C Q35621312-22F1AD60-866C-4CD2-8C6B-FFD317FF058A Q35785037-31618544-BF56-4EE3-8F72-38E80C374BA4 Q36237963-A1546076-9BFC-44A4-AB89-5D62B08CC165 Q36326113-F8A3DA0A-10EC-40D8-9E35-842AC1FCF58D Q36385190-25CBA48A-DAA0-4A1C-9760-C16C9DAAF1D4 Q36638074-EF6C8971-0DB5-44E4-A4D1-6BFC42749A5D Q36693594-AEF5CC60-F357-4CCC-83E6-62DC0AB236AA Q36789998-AEE7D55F-BF1C-417A-BF43-0A08E7E55986 Q36859211-93605469-7C07-4D42-9474-8C24A83F2859 Q37066397-55FF0F54-FEF4-4492-829A-5197488F3F8F

P2860

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

http://www.wikidata.org/entity/Q35596530

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Natural history of compensated ...... erarchy of major complications

@ast

Natural history of compensated ...... erarchy of major complications

@en

type

label

Natural history of compensated ...... erarchy of major complications

@ast

Natural history of compensated ...... erarchy of major complications

@en

prefLabel

Natural history of compensated ...... erarchy of major complications

@ast

Natural history of compensated ...... erarchy of major complications

@en

P1433

Q35596530-785EC0F4-8D44-4592-964E-BCA06FE74A56

P1476

Q35596530-254C2284-6801-4CB6-89AD-7A0DDEAA38CC

P2093

Q35596530-0C744869-520E-4B01-9EFD-82BE10EC0540

Q35596530-376C5FFF-AC1E-4844-ACE1-1A3019E169B7

Q35596530-C12E7845-4C18-4DDC-A8D6-93E5CA7B7EF1

Q35596530-F3A32903-A855-4611-BFBC-3D0383EA5B20

P2860

Q35596530-05CF6705-3FE7-402F-B4BD-87184BDA6A55

Q35596530-13FD531E-CAD1-438E-A6D1-73B63114C9DE

Q35596530-24A52F0D-C7E8-4DFD-82A6-439E306E50A1

Q35596530-2776370A-CFD3-488D-8D0B-8C8242F82AA7

Q35596530-33AAEE0F-E6E0-47A7-A0FA-A0DE82963F1E

Q35596530-4507066E-428F-4531-8656-D9E974FD8742

Q35596530-49124B8F-66F9-4CD9-AF67-965F31C91E66

Q35596530-497D3CF0-68BB-4B69-BEC4-669E1115053E

Q35596530-63EFAFA3-F477-4B71-B418-8E0739830CBD

Q35596530-72AEC710-B9A0-4E94-AB18-1CC09437D9D6

P304

Q35596530-14B45BDC-E3AB-4777-951D-B77DB0C5137F

P31

Q35596530-879505DE-88CE-4F16-9652-94973BC2BC48

P356

Q35596530-AA90DF7B-105E-4272-8CA7-4B7C932D0F1B

P407

Q35596530-0534487C-7DAB-4D2E-830A-89F19C0B1130

P433

Q35596530-451768CB-9235-4989-AB49-F680970184C5

P478

Q35596530-CCA40A08-4A51-4F4D-A876-913C4EC27946

P577

Q35596530-3C8E58A7-454C-487D-BF9A-5EDB28DCD1A4

P5875

Q35596530-36D06082-E87C-4D2A-9E68-D6E7612A2130

P698

Q35596530-9E7C48F1-5FC6-4D10-AA98-8E109D0B0642

P932

Q35596530-577660E5-33C0-4292-B4E4-BABE3E3A6897

P356

GUT.2003.020263

P1433

P1476

Natural history of compensated ...... erarchy of major complications

@en

P2093

Alberti A

http://www.w3.org/2001/XMLSchema#string

Benvegnù L

http://www.w3.org/2001/XMLSchema#string

Boccato S

http://www.w3.org/2001/XMLSchema#string

Gios M

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

Natural history of hepatitis C.

Management of hepatitis B: 2000--summary of a workshop.

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

Hepatitis B: evolving epidemiology and implications for control.

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.

Survival and prognostic indicators in compensated and decompensated cirrhosis.

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis.

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

P304

744-749

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.2003.020263

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277543480

http://www.w3.org/2001/XMLSchema#string

P698

15082595

http://www.w3.org/2001/XMLSchema#string

P932

1774055

http://www.w3.org/2001/XMLSchema#string